P = .18) or new-onset DME (7390 [22.6%] vs 7425 [22.7%] events
Semaglutide: A Game-Changer in Weight Loss Semaglutide, originally developed as a treatment for type 2 diabetes, has gained attention for its secondary benefit significant weight loss
Recent studies indicate that individuals who underwent bariatric surgery and then used Wegovy experienced significant additional weight loss, enhancing the overall effectiveness of their surgical intervention
They have not gone through the strict safety, dosage, or absorption testing required for FDA-approved drugs
Although this evidence is currently based on animal studies, it is hoped that these findings can be replicated in humans
dr Frenzel is a triple board-certified, dual fellowship-trained bariatric and cosmetic surgeon with over 15 years of experience